+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic value of a 92-probe signature in breast cancer

Prognostic value of a 92-probe signature in breast cancer

Oncotarget 6(17): 15662-15680

Clinical applications of gene expression signatures in breast cancer prognosis still remain limited due to poor predictive strength of single training datasets and appropriate invariable platforms. We proposed a gene expression signature by reducing baseline differences and analyzing common probes among three recent Affymetrix U133 plus 2 microarray data sets. Using a newly developed supervised method, a 92-probe signature found in this study was associated with overall survival. It was robustly validated in four independent data sets and then repeated on three subgroups by incorporating 17 breast cancer microarray datasets. The signature was an independent predictor of patients' survival in univariate analysis [(HR) 1.927, 95% CI (1.237-3.002); p < 0.01] as well as multivariate analysis after adjustment of clinical variables [(HR) 7.125, 95% CI (2.462-20.618); p < 0.001]. Consistent predictive performance was found in different multivariate models in increased patient population (p = 0.002). The survival signature predicted a late metastatic feature through 5-year disease free survival (p = 0.006). We identified subtypes within the lymph node positive (p < 0.001) and ER positive (p = 0.01) patients that best reflected the invasive breast cancer biology. In conclusion using the Common Probe Approach, we present a novel prognostic signature as a predictor in breast cancer late recurrences.

(PDF emailed within 1 workday: $29.90)

Accession: 058637591

Download citation: RISBibTeXText

PMID: 25883221

Related references

Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer. Oncotarget 6(42): 44593-44608, 2016

A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. Oncotarget 7(42): 68012-68022, 2016

Autophagy-related prognostic signature for breast cancer. Molecular Carcinogenesis 55(3): 292-299, 2016

A molecular signature of the Nottingham prognostic index in breast cancer. Cancer Research 64(9): 2962-2968, May 1, 2004

Gene-signature-based prognostic tools in breast cancer: not yet. Lancet 369(9571): 1428, 2007

The 70-gene prognostic signature for korean breast cancer patients. Journal of Breast Cancer 14(1): 33-38, 2011

The prognostic role of a gene signature from tumorigenic breast-cancer cells. New England Journal of Medicine 356(3): 217-226, 2007

A prognostic DNA signature for T1T2 node-negative breast cancer patients. Genes, Chromosomes and Cancer 49(12): 1125-1134, 2011

A robust prognostic signature for hormone-positive node-negative breast cancer. Genome Medicine 5(10): 92, 2013

A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Research and Treatment 126(2): 407-420, 2011

An iron regulatory gene signature in breast cancer: more than a prognostic genetic profile?. Future Oncology 8(2): 131-134, 2012

The E2F4 prognostic signature is also predictive of the pathological response of breast cancer to chemotherapy. Breast Cancer Research 17: 54, 2015

Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. Bmc Cancer 14: 177, 2014

A breast cancer prognostic signature predicts clinical outcomes in multiple tumor types. Oncology Reports 24(2): 489-494, 2010